agilon health, inc. (AGL) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents mixed signals: while there are improvements in cash position and some positive financial metrics, the overall financial performance remains negative with significant losses and cost trends. The Q&A section highlights concerns about cost trends and unclear management responses, which could weigh on investor sentiment. The company's strategic focus on cost reduction and improved payer contracts is promising, but the lack of clear guidance on certain issues tempers optimism. Considering the company's market cap, the stock price is likely to remain relatively stable, resulting in a neutral sentiment.
Key Financial Performance
Total Revenue (Q4 2025) $1.57 billion, reflecting the impact of lower-than-expected risk adjustment revenue and previously disclosed market and payer contract exits.
Total Revenue (Full Year 2025) $5.93 billion, reflecting the impact of lower-than-expected risk adjustment revenue and previously disclosed market and payer contract exits.
Medical Margin (Q4 2025) Negative $74 million, reflective of elevated cost trend assumptions and previously discussed risk adjustment impact.
Medical Margin (Full Year 2025) Negative $57 million, reflective of elevated cost trend assumptions, negative $60 million from exited markets, and negative $53 million from prior year development.
Adjusted EBITDA (Q4 2025) Negative $142 million, reflecting elevated cost trends, lower geography entry costs, and continued operating cost discipline.
Adjusted EBITDA (Full Year 2025) Negative $296 million, reflecting elevated cost trends, lower geography entry costs, and continued operating cost discipline.
ACO REACH Adjusted EBITDA (Q4 2025) Negative $6 million, in line with expectations.
ACO REACH Adjusted EBITDA (Full Year 2025) $41 million, demonstrating the value creation of the total care model.
Cash and Marketable Securities (Year-End 2025) $285 million, ahead of expectations by $66 million, including $34 million in permanent improvement and $32 million related to expense timing.
Off-Balance Sheet Cash (Year-End 2025) $91 million held by ACO entities.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Clinical Pathways: Advanced clinical pathways for chronic conditions like heart failure, dementia, and COPD, with over 90% network adoption for heart failure programs.
Palliative Care: Expanded palliative care programs to improve quality of life and reduce avoidable late-stage utilization.
ACO REACH Program: Strong performance in ACO REACH, with 114,000 members at year-end 2025, and shaping the transformation of the MA business.
LEAD Program: CMS announced the LEAD program, a 10-year voluntary model to replace ACO REACH, emphasizing high-need patient care.
Data Pipeline Enhancements: Improved financial data pipeline and analytical capabilities for better financial discipline and predictability.
Cost Reductions: Achieved $35 million in operating cost reductions in 2025, exceeding prior targets.
Contracting Strategy: Prioritized economic sustainability over membership growth by exiting unprofitable payer contracts and restructuring arrangements.
Quality Initiatives: Enhanced quality programs, achieving 4.2 stars on a composite basis and doubling incentive contributions for 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Lower-than-expected rate increase in 2027: The potential for a lower-than-expected rate increase in 2027 following CMS's advanced rate notice could adversely impact financial performance. The notice does not sufficiently reflect the ongoing population-wide increase in cost and utilization due to growing chronic disease burden and aging of the Medicare population.
Risk model revision and normalization: Changes in the risk model and normalization outlined in the CMS advanced notice could impact financial outcomes. Although the company believes the impact will align with the national average, it remains a potential challenge.
Elevated medical cost trends: Medical cost trends are expected to remain elevated in 2026 at approximately 7%, which could strain financial performance and profitability.
Exiting unprofitable payer contracts: The decision to exit certain payer contracts in specific markets due to lack of profitability reduces membership and revenue, potentially impacting scale and market presence.
Reduction in Medicare Part D exposure: Reducing exposure to Medicare Part D to less than 15% of membership could limit revenue opportunities, despite being aimed at improving profitability.
Market exits and membership reduction: Exiting certain markets and reducing membership to approximately 430,000 members in 2026 could impact revenue and growth potential.
Regulatory and policy changes: Uncertainty around regulatory changes, such as the CMS advanced rate notice and ACO REACH program adjustments, could create financial and operational challenges.
Increased inpatient costs: Elevated inpatient costs, including large discrete claims, have contributed to higher medical cost trends, impacting margins.
Operational cost pressures: Despite cost reduction initiatives, ongoing pressures from employee merit increases, medical cost inflation, and incentive compensation expenses could strain profitability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: For 2026, the company expects revenues in the range of approximately $5.41 billion to $5.58 billion.
Medical Margin and Adjusted EBITDA: The company anticipates a medical margin of $300 million to $350 million in 2026 and adjusted EBITDA in the range of negative $15 million to positive $15 million, or breakeven at the midpoint.
Membership Projections: Year-end membership on the agilon platform is expected to range from 525,000 to 540,000 members, including 430,000 Medicare Advantage members and approximately 103,000 ACO model members.
Cost Trends: The company assumes a gross cost trend of 7.5% for 2026, with a net cost trend of 7% after considering a 50 basis points benefit from payer bids.
Capital Position: The company expects to end 2026 with at least $125 million of cash on hand, including ACO REACH entities.
Payer Contracting and Quality Incentives: The company expects to benefit from payer bids focused on margin improvement, including premium increases, deductible adjustments, and reductions in supplemental benefits. Quality incentive opportunities are expected to more than double compared to 2025.
Clinical Pathways and Chronic Disease Management: The company plans to continue advancing clinical pathways for conditions like heart failure, dementia, and COPD, which are expected to improve patient outcomes and reduce total cost of care.
Regulatory and Market Dynamics: The company is analyzing the CMS advanced rate notice and expects its burden of illness and clinical pathway initiatives to mitigate potential impacts from risk model revisions.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the cost trend for 2025 and what factors influenced it?
A:The cost trend for 2025 is set at 6.5%. Factors influencing this include higher inpatient stays in Q3, with several cases over $1 million aggregating to $6.5 million. The Q3 cost trend was adjusted from the low 6s to 7.2%, and Q4 was set at 7.4%, raising the full-year trend to 6.5%.
Q:What actions are planned for 2027 regarding MA and ACO?
A:For 2027, actions include contracting, burden of illness programs, and payer bid evaluations. The ACO model is seen as a 10-year opportunity, with ongoing advocacy for policy clarity and program development.
Q:Were the incremental inpatient admit costs in Q3 tied to specific payers or geographies?
A:No, the costs were not concentrated in specific markets but were seen in several markets, particularly in inpatient stays. September was the highest month for these costs. The Q4 reserving of 7.4% assumes a prudent cushion due to limited claims visibility.
Q:Are there additional opportunities for cost streamlining in 2026?
A:Yes, there are further opportunities for cost reduction, including automation, AI, and technology, though these may be harder to achieve.
Q:What is the update on the '25 fee-for-service trend within ACO REACH?
A:The fee-for-service cost trend for 2025 is 8.1%, down from 8.5%. Cost trends were tilted toward the back half of the year.
Q:What are the notable areas for improvement in the CMS rate notice?
A:Notable areas include the treatment of skin substitutes and risk model recalibration. The company seeks rates that account for recent cost trends and hopes for delays or adjustments to balance cost dynamics.
Q:What is the current mix of group MA and its impact on guidance?
A:The mix of group MA is not expected to differ significantly heading into 2026. Final membership data will be available towards the end of Q1 2026.
Q:What is the progress on quality measures and opportunities for 2026?
A:For 2025, the company is close to achieving its $25 million quality target. For 2026, the opportunity doubles, with programs focused on driving performance. The guide assumes similar performance to 2025.
Q:What is the company's view on the CMS advanced notice and cost trends?
A:The company aligns with the effective growth rate outlined in the CMS advanced notice. It has shown the ability to offset risk model changes like V28 and plans to implement additional clinical pathways to manage conditions like congestive heart failure.
Q:What is the exposure to special need plans and their margin opportunity?
A:Special need plans account for roughly 7% of the company's mix. There is no current indication of a significant mix shift.
Q:What is the company's approach to payer contracts and membership exits?
A:The company has walked away from contracts where economics and risk were not favorable. This decision is payer and market-specific, and there is potential to revisit these contracts in the future.
Q:What is the company's perspective on the disconnect between CMS cost trends and industry trends?
A:The company acknowledges a disconnect between CMS's 5.5% cost trend and the industry's higher trends. It advocates for a revisit of the initial rate notice to address this gap.
Q:What is the company's exposure to chart review and risk model changes?
A:The company has minimal exposure to unlinked conditions due to its model's alignment with primary care physicians. It is exposed to Part C risk model changes, which vary by market.
Q:What are the new geography entry expenses for 2026?
A:The $15 million in new geography entry expenses for 2026 are capital commitments from prior growth and some ongoing discussions with other groups.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer on the following: 1) Specific details on the mix shift towards special need plans and its structural margin opportunity. 2) The exact breakdown of the $127 million payer contract improvement between percent of premium changes and Part D risk. 3) Specific payer or market details regarding membership exits and recontracting. 4) Detailed explanation of the disconnect between CMS's cost trends and industry trends, beyond general advocacy for revisiting the rate notice.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ACO design
AI advance
CHF pathway
CMS commitment
CMS lead
COPD cancer
COPD utilization
Congestive heart
LEAD
advancement
agilon model
care coordination
care gap
care model
community
condition
contracting
coordination fee
cost care
diagnosis
emphasis
fee arrangement
goal
health plan
identification
improvement margin
improvement result
life care
model term
network quality
payer contract
population
premium
program term
result ACO
risk model
stage
structure
sustainability
transformation
value care
AGL Transcript
agilon health, inc. (AGL) Q1 2026 Earnings Call Transcript
Unknown5-6
The company's earnings call presents a mix of positive and cautious elements. While there is optimism in revenue expectations and strategic initiatives, uncertainties in payer incentives and lack of clarity on AI risk adjustments temper enthusiasm. The market cap suggests moderate volatility, aligning with a neutral sentiment as the company navigates both growth opportunities and operational challenges.
agilon health, inc. (AGL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-10
agilon health, inc. (AGL) Q4 2025 Earnings Call Transcript
Unknown2-26
The earnings call summary presents mixed signals: while there are improvements in cash position and some positive financial metrics, the overall financial performance remains negative with significant losses and cost trends. The Q&A section highlights concerns about cost trends and unclear management responses, which could weigh on investor sentiment. The company's strategic focus on cost reduction and improved payer contracts is promising, but the lack of clear guidance on certain issues tempers optimism. Considering the company's market cap, the stock price is likely to remain relatively stable, resulting in a neutral sentiment.
agilon health, inc. (AGL) Q3 2025 Earnings Call Transcript
Unknown11-4
The earnings call summary presents a mixed picture. While there are strategic plans for 2026, current issues like the negative impact of ACO REACH program changes and unclear management responses create uncertainty. The Q&A section highlights concerns about profitability and contract renewals, but also notes potential improvements in 2026. The market cap suggests moderate volatility, leading to a neutral sentiment as the stock may not significantly move in either direction over the next two weeks.
AGL Slides
AGL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
